Close Menu
NEW YORK (GenomeWeb News) – Claire Fraser-Liggett has resigned as president of the Institute for Genomic Research and will leave TIGR on April 20, GenomeWeb has learned.
 
It was not immediately clear who will take her place at TIGR, which is a division of the J. Craig Venter Institute.
 
News of Fraser-Liggett’s departure was disclosed in an e-mail sent to JCVI colleagues by Craig Venter, JCVI president and CEO, which said she will leave “to pursue a new position.” 
 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.

Oct
21
Sponsored by
Roche

Target enrichment has been a major driver behind the clinical adoption of next-generation sequencing (NGS) over the last decade because it simplifies analysis and provides a cost-effective method of massive parallel resequencing. It has not only replaced Sanger sequencing, but it is actively dispensing the need for parallel copy number variant (CNV) analysis using classic techniques.